Related Experiment Video
Updated: May 17, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
Published on: April 29, 2014
Englerin a selectively induces necrosis in human renal cancer cells
Florian J Sulzmaier1, Zhenwu Li, Mika L Nakashige
1Cancer Biology Program, University of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, Hawaii, United States of America.
Abstract:
The number of renal cancers has increased over the last ten years and patient survival in advanced stages remains very poor. Therefore, new therapeutic approaches for renal cancer are essential. Englerin A is a natural product with a very potent and selective cytotoxicity against renal cancer cells. This makes it a promising drug candidate that may improve current treatment standards for patients with renal cancers in all stages. However, little is known about englerin A's mode of action in targeting specifically renal cancer cells. Our study is the first to investigate the biological mechanism of englerin A action in detail. We report that englerin A is specific for renal tumor cells and does not affect normal kidney cells. We find that englerin A treatment induces necrotic cell death in renal cancer cells but not in normal kidney cells. We further show that autophagic and pyroptotic proteins are unaffected by the compound and that necrotic signaling in these cells coincided with production of reactive oxygen species and calcium influx into the cytoplasm. As the first study to analyze the biological effects of englerin A, our work provides an important basis for the evaluation and validation of the compound's use as an anti-tumor drug. It also provides a context in which to identify the specific target or targets of englerin A in renal cancer cells.
Insights
Englerin A, a natural compound, shows potent and selective toxicity against renal cancer cells, inducing necrotic cell death. This study details its specific mechanism, offering a promising new therapeutic avenue for kidney cancer treatment.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Renal cancer incidence is rising, with poor survival rates in advanced stages, necessitating novel therapeutic strategies.
- Englerin A, a natural product, exhibits potent and selective cytotoxicity against renal cancer cells, indicating its potential as a drug candidate.
- The precise mechanism by which Englerin A targets renal cancer cells remains largely uncharacterized.
Purpose of the Study:
- To elucidate the biological mechanism of Englerin A's action in renal cancer cells.
- To determine the specificity of Englerin A for tumor cells versus normal kidney cells.
- To investigate the type of cell death induced by Englerin A and associated signaling pathways.
Main Methods:
- Cell-based assays to assess cytotoxicity and specificity against renal cancer and normal kidney cells.
- Analysis of cell death pathways, including apoptosis, autophagy, and pyroptosis.
- Measurement of reactive oxygen species production and intracellular calcium levels following Englerin A treatment.
Main Results:
- Englerin A demonstrated high specificity for renal tumor cells, with no observed toxicity in normal kidney cells.
- Treatment with Englerin A induced necrotic cell death exclusively in renal cancer cells.
- Necrotic cell death in renal cancer cells was associated with increased reactive oxygen species and calcium influx, while autophagic and pyroptotic pathways were unaffected.
Conclusions:
- Englerin A is a specific cytotoxic agent for renal cancer cells, inducing cell death via necrosis.
- The findings provide a foundational understanding of Englerin A's mechanism of action, supporting its potential as an anti-cancer drug.
- Further research is warranted to identify the specific molecular targets of Englerin A in renal cancer cells.
